Key Findings

Order Report  

Corporate Women Directors International 2006 Report:
"Women Board Directors of the
Largest Healthcare and Pharmaceutical Companies"

Key Findings

  • The good news:  the largest global healthcare and pharmaceutical companies appoint women to their boards at a slightly higher rate than the Fortune Global 200, the 200 largest companies in the world – 11.5% to 10.4%.
  • The good news:  U.S.-based healthcare and pharmaceutical companies have a better percentage of women directors at 16.4% than the national average of 14.7% among the Fortune 500.  In an industry-to-industry comparison, the healthcare companies also outpace the largest U.S. banks in terms of women board directors – 16.4% vs. 12.4%.
  • The bad news:  only 65.2% of the Financial Times 500 healthcare and pharmaceutical companies have at least one woman on their boards of directors.  This leaves 35.8% of companies without a single female director, including GlaxoSmithKline, the third largest in the world.
  • Pharmaceutical companies lag behind healthcare companies in including women on their boards – 9.6% to 14.3%. 
  • Wellpoint, a health benefits company, ranks first in CWDI’s Top Five list of healthcare and pharmaceutical companies with the highest percentage of women directors at 31.3% or 5 out of 16 directors.
  • Aetna, Astrazeneca and Johnson & Johnson all tie for second place with 30.8% of their board directors being female.
  • The largest American pharmaceutical and healthcare companies outpace their European counterparts in appointing women to corporate boards – 16.4% to 9.9%.
  • None of the 22 Japanese healthcare and pharmaceutical companies included in the Financial Times 500 listings had a single woman on their boards.
  • The percentage of women executive officers in healthcare and pharmaceutical companies (9.8%) is lower than the percentage of women directors serving on the boards of those companies (11.5%), creating a limited pool from which to draw future directors or CEOs.
  • Almost half of the companies covered in this report -- 44 out of 92 – have no senior women executive officers in their executive management team.



Copyright © 2007-2008 Globewomen. All rights reserved. "Corporate Women Directors International",
"Global Summit of Women" and "Global Diversity" are trademarks of GlobeWomen.

Any Questions & Comments, contact GlobeWomen at summit@globewomen.comOr, write to us:
Globewomen, Inc./ 666 11th St. NW, Ste. 700/ Washington, DC 20001/ USA

[GlobeWomen Home] [CWDI] [Consortium to End Cervical Cancer] [Global Diversity] [Summit]